This inventor holds 0 USPTO granted patents, plus 3 CIPO patents.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Title: The Innovations of Stephen M. Condon
Introduction
Stephen M. Condon is an accomplished inventor based in the United States. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that interact with apoptosis proteins. Although he currently holds no patents, his work has been influential in advancing therapeutic methods.
Latest Patents
Stephen M. Condon's latest patents include the "Smac Mimetic," which involves a SMAC mimetic and pharmaceutical compositions, along with methods of use. Another notable patent is for "IAP Binding Compounds," which discloses IAP binding molecules and compositions. These molecules interact with inhibitor of apoptosis proteins (IAPs) in cells, potentially modifying apoptosis in treated cells. The compounds have a Kd of less than 0.1 micromolar, and methods for their therapeutic, diagnostic, and assay applications are also described.
Career Highlights
Throughout his career, Stephen M. Condon has worked with various organizations, including Tetralogic Pharmaceuticals Corporation. His expertise in the pharmaceutical industry has allowed him to contribute to innovative solutions in drug development.
Collaborations
Stephen has collaborated with notable professionals in his field, including Matthew G. Laporte and Yijun Deng. These collaborations have further enriched his work and expanded the impact of his inventions.
Conclusion
Stephen M. Condon's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His work on IAP binding molecules and SMAC mimetics highlights the potential for new therapeutic approaches.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile